person · Reporting owner

Zaks Tal Zvi

Disclosed activity across 3 companies

Tapewire entity: 25234
SEC CIK: 0001690927

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adaptimmune Therapeutics PLCADAP · Entity 9824	Director	July 01, 2022	July 01, 2022
Moderna, Inc.MRNA · Entity 2025	Chief Medical Officer	June 30, 2021	July 02, 2021
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Director	August 05, 2026	August 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptimmune Therapeutics PLC

Report date July 01, 2022 · Filed July 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01	Direct	500,000	Reported balance After 2022-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-07-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Moderna, Inc.

Report date June 30, 2021 · Filed July 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-06-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-06-30 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. Row 2 · 2021-06-30 · Sale · Disposed 5,000 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.93 · Expires 2030-02-28	Direct	121,120	Reported balance After 2021-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-30 · Exercise / conversion · Disposed 5,000 · Balance 121,120 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021. F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.

F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date August 05, 2026 · Filed August 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	73,247	Reported balance After 2026-08-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-05 · Sale · Disposed 17 · Balance 73,247 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2020 Filed Mar 3, 2020 21:35 UTC	Moderna, Inc. MRNA · Entity 2025	SaleCommon Stock	10,000	$23.38	$233,800.00	Disclosure SEC source: 0001127602-20-009028 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 21, 2020 Filed Feb 24, 2020 21:06 UTC	Moderna, Inc. MRNA · Entity 2025	SaleCommon Stock	10,000	$18.47	$184,700.00	Disclosure SEC source: 0001127602-20-007174 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
December 12, 2019 Filed Dec 17, 2019 00:13 UTC	Moderna, Inc. MRNA · Entity 2025	SaleCommon Stock	100,000	$18.54	$1,854,000.00	Disclosure SEC source: 0001127602-19-035092 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,770 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.33 to $19.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document
July 02, 2019 Filed Jul 3, 2019 21:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	124,000	$0.00 Strike: $0.61	$0.00	Disclosure SEC source: 0001104659-19-039327 · a4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2029-07-02 F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
March 08, 2019 Filed Mar 11, 2019 21:29 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	339,195	$0.00 Strike: $20.93	$0.00	Disclosure SEC source: 0001127602-19-010855 · form4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,195 Underlying: Common Stock · 339,195 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	124,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001104659-18-042322 · a4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
July 03, 2017 Filed Jul 3, 2017 21:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	144,000	$0.00 Strike: $0.75	$0.00	Disclosure SEC source: 0001104659-17-043266 · a4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Ordinary Shares · 144,000 shares Expires 2027-07-03 F1 · derivative.exercise_price: The exercise price was converted from GBP0.58 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. Read SEC document
November 29, 2016 Filed Dec 1, 2016 21:30 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	288,000	$0.00 Strike: $0.81	$0.00	Disclosure SEC source: 0001104659-16-160131 · a4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Ordinary Shares · 288,000 shares Expires 2026-11-29 F1 · derivative.exercise_price: The exercise price was converted from GBP0.65 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 72,000 Ordinary Shares on November 29, 2017 and will be exercisable as to the remainder in monthly installments of 9,000 Ordinary Shares on the twenty-ninth of each month from December 29, 2017 through November 29, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.